Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Ir J Med Sci ; 192(1): 27-31, 2023 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-35094231

RESUMEN

BACKGROUND: Multiparametric magnetic resonance imaging (mpMRI) has been increasingly recognised as an important tool in the diagnosis of prostate cancer. PI-RADSv2 guidelines recommend that important clinical information including prostate-specific antigen (PSA) levels, examination findings, and biopsy information should be included in mpMRI requests. PIRADS score and PSA density (PSAD) are both independent predictors for the presence of a clinically significant prostate cancer. AIMS: This study aims to evaluate the quality of mpMRI requests and reports at our institution in accordance with these parameters. METHODS: All prostate mpMRIs performed by radiology services in Galway University Hospital between 1st September 2019 and 1st March 2020 were reviewed. Exclusion criteria were applied. Requests and reports were analysed for the presence of the following parameters: PSA-results, examination findings, biopsy information, PI-RADS score, prostate volume, and PSAD. RESULTS: A total of 586 mpMRIs were performed, and of these, 546 were included. PSA value was provided in 497 (91%) of requests, exam findings in 355 (65%), and biopsy information in 452 (82%). PIRADS score was included in 224 (41%) of reports, prostate volume in 178 (32.6%), and PSAD in 106 (19%). CONCLUSIONS: Great variation in the quality of information contained in both requests and reports for prostate mpMRIs exists within our service. We aim to improve this by collaborating with our radiology colleagues to develop a proforma for requesting and reporting of mpMRIs for our radiology systems to ensure important clinical and radiological information is provided in future.


Asunto(s)
Imágenes de Resonancia Magnética Multiparamétrica , Neoplasias de la Próstata , Masculino , Humanos , Próstata/diagnóstico por imagen , Próstata/patología , Neoplasias de la Próstata/patología , Antígeno Prostático Específico , Imagen por Resonancia Magnética/métodos , Estudios Retrospectivos , Biopsia Guiada por Imagen/métodos
2.
Ir J Med Sci ; 191(6): 2771-2775, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-35037159

RESUMEN

BACKGROUND: The Bosniak classification is a CT classification which stratifies renal cysts based on imaging appearances and therefore associated risk of malignancy. Bosniak IIf cysts are renal which have complex features and therefore require surveillance. AIMS: The aim of this study is to assess the economic and workload burden of diagnosing and following up Bosniak IIf cysts on the urology service in a tertiary hospital in the West of Ireland. METHODS: All patients with a diagnosis of Bosniak IIf renal cysts attending our urology service between 1st of January 2012 and 31st December 2020 were analysed. The following data were collected: number and modality of follow up scans, number of MDT discussions, number and type of outpatient appointments, surgical intervention, and length of follow up. Financial data were provided by the hospital finance department. RESULTS: One hundred and sixty-two patients were included. Total cost of follow up was €164,056, costing €1,012.7 per patient. Cost of outpatient visits was €77,850. Follow-up length ranged from 1 to 109 months, median follow up time 17.5 months. Overall cost of imaging was €74,518. There were a total of 80 MDT discussions at an overall cost of €11,688. CONCLUSIONS: This study demonstrates that surveillance of patients with Bosniak IIf renal cysts represents a significant burden upon both radiology and urology services. Surveillance for these patients could be streamlined in the future through a number of initiatives such as virtual OPDs and dedicated MDTs.


Asunto(s)
Quistes , Enfermedades Renales Quísticas , Neoplasias Renales , Humanos , Centros de Atención Terciaria , Estrés Financiero , Carga de Trabajo , Enfermedades Renales Quísticas/diagnóstico por imagen , Enfermedades Renales Quísticas/epidemiología , Neoplasias Renales/patología , Estudios Retrospectivos
3.
Ir J Med Sci ; 189(3): 811-815, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-31838732

RESUMEN

BACKGROUND: The Movember campaign encourages men to grow a moustache during the month of November. The campaign's aims include promotion of prostate and testicular cancer awareness. AIMS: To examine the effectiveness of the Movember campaign at generating awareness of prostate and testicular cancers by examining Internet search activity. METHODS: Google Trends was used to review weekly Internet search activity from January 2004 to December 2015. We reviewed search activity for the search terms "prostate cancer", "testicular cancer", "Movember" and "moustache". The weeks in November from 2004 to 2015 were examined for changes in search activity for our chosen search terms, which could be attributed to the annual Movember campaign. Search activity was recorded weekly and scored from 0 to 100 with 100 representing peak search activity. RESULTS: Mean search activity for each term during the weeks of Movember campaign. However, throughout the 11 years assessed, only the term "moustache" was consistently statistically associated with increasing publicity for the Movember campaign. Cancer awareness was inconsistent. Testicular cancer shows a significant association in only one of the 11 years and prostate cancer in only 2 years. CONCLUSION: We concluded that the Movember campaign is consistently linked in the public consciousness with novelty facial hair and only weakly associated with an awareness of prostate and testicular cancers. Whilst the funding generated by the campaign should be commended, more could be done to link the campaign and moustaches to awareness of common male cancers.


Asunto(s)
Internet/normas , Salud del Hombre/normas , Neoplasias de la Próstata/epidemiología , Neoplasias Testiculares/epidemiología , Adulto , Humanos , Masculino
4.
Urology ; 114: 133-138, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-29410311

RESUMEN

OBJECTIVE: To determine the pathologic findings and clinical outcome of patients with pure embryonal carcinoma (EC) of the testis who were diagnosed with testis cancer from January 1989 to January 2013 who underwent an orchiectomy, cisplatin-based chemotherapy and a postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). METHODS: We compared those patients with 100% EC with those with mixed nonseminomatous germ cell tumor pathology who underwent a PC-RPLND. RESULTS: Of 1105 patients who underwent a PC-RPLND, 145 had pure EC. Twenty-six percent of patients presented with metastatic disease outside the retroperitoneum. Patients with mixed histologies tended to have worse International Germ Cell Cancer Collaborative Group risk compared to those with EC at orchiectomy (P = .037). Histology at PC-RPLND revealed fibrosis or necrosis in 76%, mature teratoma in 19% and viable cancer in 4%. Over one-third of the patients had a residual mass of <1 cm prior to RPLND; of whom 15% harbored mature teratoma in PC-RPLND histology. The Kaplan-Meier estimated probability of recurrence at 5 years of follow-up was 3.1% (95% CI 1.2%, 8.0%) for EC histology, 7.3% lower than mixed histology. For cancer-specific mortality, the Kaplan-Meier estimated probability at 5 years was 4.6% (95% CI 3.3%, 6.3%) and 1.7% (95% CI 0.4%, 6.8%) for mixed and pure EC histologies, respectively. CONCLUSION: Approximately 20% of patients with pure EC had teratoma at PC-RPLND. We have shown that those with a maximum node size of <1 cm should not be precluded from RPLND.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma Embrionario/terapia , Escisión del Ganglio Linfático , Ganglios Linfáticos/patología , Neoplasias Complejas y Mixtas/terapia , Neoplasias de Células Germinales y Embrionarias/terapia , Teratoma/terapia , Neoplasias Testiculares/terapia , Adulto , Carcinoma Embrionario/secundario , Quimioterapia Adyuvante , Cisplatino/administración & dosificación , Progresión de la Enfermedad , Supervivencia sin Enfermedad , Fibrosis , Humanos , Estimación de Kaplan-Meier , Metástasis Linfática , Masculino , Persona de Mediana Edad , Necrosis , Neoplasia Residual , Neoplasias Complejas y Mixtas/secundario , Neoplasias de Células Germinales y Embrionarias/secundario , Orquiectomía , Espacio Retroperitoneal , Estudios Retrospectivos , Tasa de Supervivencia , Teratoma/secundario , Neoplasias Testiculares/patología , Neoplasias Testiculares/secundario
5.
Prostate ; 71(2): 111-24, 2011 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-20665530

RESUMEN

BACKGROUND: While locally advanced prostate cancer is initially treatable with androgen ablation, eventually cells develop a castrate-resistant phenotype. Currently, there are no effective treatments for this form of the disease with Docetaxel only providing a small survival advantage. In this study, the effects of novel derivatives of titanocene dichloride on prostate cancer cell lines has been investigated. METHODS: Cellular effects were assessed using the crystal violet assay and the clonogenic survival assay. Cell cycle and apoptosis were assessed by propidium iodide staining. DNA damage was analyzed by comet assay and Western analysis. DNA damage response inhibition was achieved by pre-incubation with an ATM/ATR inhibitor; CGK733 and DNA-PK inhibitor; DMNB. RESULTS: These analogs caused a reduction in cell number. In particular titanocene Y and C had significant effects in all cell lines. A reduction in clonogenic survival was found in response to titanocene Y in three cell lines while the PC-3 cells exhibited increased resistance.Further analysis showed no effect on cell cycle however, the analogs were found to induce apoptosis in a dose-dependent manner in all cell lines. These analogs associate with DNA, induce DNA damage and a differential damage response. Inhibition of key regulators of this DNA damage response sensitized the PC-3 cell line to titanocene-induced apoptosis and significantly reduced the clonogenic capacity of the cells. CONCLUSION: These results demonstrate the mechanism of action of these novel titanocene dichloride analogs and their potential use in castrate-independent advanced prostate cancer.


Asunto(s)
Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Daño del ADN , Compuestos Organometálicos/farmacología , Neoplasias de la Próstata/tratamiento farmacológico , Apoptosis/genética , Western Blotting , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Ensayo Cometa , Violeta de Genciana/química , Humanos , Masculino , Neoplasias Hormono-Dependientes/tratamiento farmacológico , Neoplasias Hormono-Dependientes/genética , Neoplasias Hormono-Dependientes/patología , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/patología , Titanio/química
6.
Urology ; 70(4): 812.e3-6, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17991576

RESUMEN

We report the case of a 71-year-old male who presented with squamous cell carcinoma of the renal pelvis in a solitary functioning kidney, 34 years after orchidectomy and adjuvant retroperitoneal radiotherapy for stage II seminoma. This rare second malignancy occurred in the radiation treatment field. Second malignancies are an uncommon but serious sequela of radiotherapy, with potential for significant health problems in patients with complete remission of primary disease. To our knowledge, this is the first report of squamous cell carcinoma of the renal pelvis occurring after radiation treatment.


Asunto(s)
Carcinoma de Células Escamosas/etiología , Neoplasias Renales/etiología , Neoplasias Inducidas por Radiación , Neoplasias Primarias Secundarias/etiología , Seminoma/radioterapia , Neoplasias Testiculares/radioterapia , Anciano , Humanos , Pelvis Renal , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA